PATHOLOGY

PharmDx | PD-L1 – Comprehensive Education for the Entire Lab

Dako

Agilent Pathology Solutions

PD-L1 Webinar Series - a Comprehensive Education for the Entire Lab

2017 Educational Program



LEARN
how to evaluate and interpret PD-L1 stained slides

UNDERSTAND
the core principles of PD-L1 pathology

PD-L1 – Comprehensive Education for the Entire Lab

Agilent would like to invite the entire pathology laboratory to a complete educational PD-L1 program.

This program is a part of a comprehensive PD-L1 offering which also includes Interpretation Manuals and interactive e-Learning Programs at **www.agilent.com.**

The 2017 Educational Program consists of a series of webinars which can either be attended live or on-demand. You can sign up for the entire program or for the individual topics you find most relevant.

Please visit **www.dako.com/webinar** for online registration.

Moderator

Prof. Dr. Rector Magnificus Han J. M. van Krieken,
Radboud University, Nijmegen, The Netherlands

A Blueprint for PD-L1 Testing - Development and Value of the PD-L1 22C3 Assay

Kenneth J. Bloom, *Head of Oncology and Immunotherapy, Human Longevity, Inc., San Diego, USA*

Learn more about the documented evidence for the various PD-L1 clones for IHC testing. The session will cover key considerations when implementing PD-L1 testing in your lab to secure optimal and correct PD-L1 results.

Recommended Audience: Pathologists and Lab Managers
Date and Time: April 6, 2017, 17:00-18:00 CET

How to Easily and Simply Implement PD-L1 Testing in Your Lab - Verification/Validation

Carol Cheung*, MD, PhD, JD, University Health Network, University of Toronto, Canada*

Discussion of real-world examples of successful implementation of PD-L1 testing of NSCLC specimens in a clinical routine setting. A solid overview of applicable guidelines for implementing PD-L1 in your laboratory.

Recommended Audience: Pathologists, Lab Managers and other lab personnel
Date and Time: April 20, 17.00-18.00 CET

Basic Interpretation of PD-L1 Expression

Professor Bharat Jasani*, Targos Molecular Pathology GmbH, Kassel, Germany*

Learn how to evaluate and interpret Dako PD-L1 22C3 IHC pharmDx results in NSCLC with examples from real patient cases.

Recommended Audience: *This session is relevant for pathologists for whom PD-L1 testing is new, or pathologists who are looking for a practical introduction to Dako PD-L1 22C3 IHC pharmDx interpretation.*
Date and Time: *June 1, 2017, 17:00-18:00 CET*

Advanced PD-L1 Interpretation

Professor Hans-Ulrich Schildhaus, *University Medical Center Göttingen, Germany*

In-depth interpretation of Dako PD-L1 22C3 IHC pharmDx with focus on real patient cases and presentation of challenging examples.

Recommended Audience: This session is designed for pathologists who have already implemented PD-L1 testing, or will do so in the near future.
Date and Time: September 27, 2017, 17:00-18:00 CET

The Value of Participation in a PD-L1 EQA Program / PD-L1 Implementation in EQA Programs

Professor Mogens Vyberg*, University Hospital Aalborg, Denmark and*
Andreas Scheel, *M.D., University Hospital Cologne, Germany*

In this session, you will learn more about how participation in an EQA program can improve and ease your routine PD-L1 testing process and help your laboratory maintain reporting of high-quality results to the treating physician.

Recommended Audience: Pathologists and Lab Managers
Date and Time: October 26, 2017, 17:00-18:00 CET

Intended Use
For in vitro diagnostic use.

PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). See the KEYTRUDA® product label for expression cutoff values guiding therapy in specific clinical circumstances.

Trusted Answers. Together.

Dako

Agilent Pathology Solutions

www.agilent.com

Represented in more than 100 countries

Australia
+61 1800 802 402

Austria
+43 1 408 43 34 0

Belgium
+32 16/93 00 30

Brazil
+55 11 50708300

Canada
+1 800 387 8257

China
+80 08 20 3278

Denmark
+45 44 85 97 56

Finland
+358 9 348 73 950

France
+33 1 64 53 61 44

Germany
+49 40 69 69 470

Ireland
+353 1 479 0568

Italy
+39 02 58 078 1

Japan
+81 3 5232 9970

Korea
+82 80 004 5090

The Netherlands
+31 20 42 11 100

Norway
+47 23 14 05 40

Poland
+48 58 661 1879

Spain
+34 93 344 57 77

Sweden
+46 8 556 20 600

Switzerland
+41 41 760 11 66

United Kingdom
+44 (0)1 353 66 99 11

United States of America
+1 805 566 6655

3550 2017FEB03 - EU/ROW Version